Workflow
非经常性损益
icon
Search documents
广东蒙泰高新纤维股份有限公司2025年第一季度报告
Core Viewpoint - The company has disclosed its first-quarter report for 2025, ensuring the accuracy and completeness of the financial information presented, and has not undergone an audit for this report [3][9][11]. Financial Data Summary - The company reported non-recurring gains of 79,672.84 yuan for the first quarter of 2025, related to tax refund procedures [3]. - The company has not made any adjustments or restatements to previous accounting data [3]. - The company has not experienced any significant changes in its financial indicators that exceed 30% [4]. Shareholder Information - The company has not reported any changes in the top ten shareholders or any significant shareholding changes due to stock lending activities [5]. Important Events - The company has obtained two new invention patents as of March 25, 2025, related to polypropylene fiber production methods [5]. - The company has not experienced any conversion of its convertible bonds during the first quarter of 2025, with a remaining total of 2,999,408 convertible bonds valued at 299,940,800 yuan [5]. Board Meeting Resolutions - The company held a board meeting on April 25, 2025, where it approved the first-quarter report, confirming compliance with legal and regulatory requirements [10][11]. - The board also approved the establishment of a public opinion management system to enhance the company's response capabilities to various public sentiments [14]. Equipment Contract Changes - The company announced changes to equipment contracts for its subsidiary, Gansu Natta New Materials Co., Ltd., due to the original supplier's inability to fulfill the contract [18][20]. - A new supplementary agreement has been signed with a different supplier to ensure the project's progress is not adversely affected [27].
浙江东晶电子股份有限公司 2025年第一季度报告
Zheng Quan Ri Bao· 2025-04-25 23:55
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:002199 证券简称:*ST东晶 公告编号:2025026 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整,不存在虚假记载、 误导性陈述或重大遗漏,并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明:保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □适用 R不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 □是 R否 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 R否 (二) 非经常性损益项目和金额 R适用 □不适用 单位:元 其他符合非经常性损益定义的损益项目的具体情况 将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 R不适用 公司不存在将《公开发行证券的公司信息披露解释性公告第1号— ...
山东南山铝业股份有限公司 2025年第一季度报告
Zheng Quan Ri Bao· 2025-04-25 23:39
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:600219 证券简称:南山铝业 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假 记载、误导性陈述或重大遗漏,并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位:元 币种:人民币 (二) 非经常性损益项目和金额 √适用 □不适用 1、国内氧化铝市场: 2025年第一季度与2024年第一季度国内氧化铝价格走势对比情况图 单位:元/吨 数据来源:阿拉丁 2025年一季度国内氧化铝价格整体呈现下跌态势。随着国内氧化铝开工产能始终处于高位、新增产能陆 续投产,供应端仍处于产能扩张期,叠加库存持续累库,国内氧化铝价格承压明显,呈现大幅回落态 势。2025年一季度国内氧化铝均价为3,983元/吨 ...
苏州海陆重工股份有限公司 2025年第一季度报告
Zheng Quan Ri Bao· 2025-04-25 23:30
Core Viewpoint - The company ensures the authenticity, accuracy, and completeness of its quarterly report, with all board members and senior management taking legal responsibility for the information disclosed [2][3]. Financial Data Summary - The quarterly report has not been audited [8]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3]. - The company has provided a detailed analysis of changes in asset composition, profit structure, and cash flow for the reporting period [4][5]. Shareholder Information - There are changes in the freeze termination dates of shares held by significant shareholders, specifically Wu Weiwen and Jubao Holdings Group Co., Ltd. [5]. - The company confirms that there are no changes in the top ten shareholders or their shareholding status due to securities lending activities [5]. Financial Statements - The company has prepared consolidated financial statements, including the balance sheet, income statement, and cash flow statement, as of March 31, 2025 [6][7]. - The net profit of the merged entity prior to consolidation remains at 0.00 yuan for both the current and previous periods [6]. Accounting Standards - The company will not apply the new accounting standards for the first time in the current reporting period [8].
上海悦心健康集团股份有限公司 2025年第一季度报告
Zheng Quan Ri Bao· 2025-04-25 23:30
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:002162 证券简称:悦心健康 公告编号:2025-034 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗 漏。 公司是否需追溯调整或重述以前年度会计数据 □是 R否 (二) 非经常性损益项目和金额 R适用 □不适用 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整,不存在虚假记载、 误导性陈述或重大遗漏,并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明:保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □是 R否 一、主要财务数据 (一) 主要会计数据和财务指标 单位:元 其他符合非经常性损益定义的损益项目的具体情况 □适用 R不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 R不适用 公司不存在将《公开发行证券的公司信息披露解释性公告第1号— ...
江西百通能源股份有限公司 2025年第一季度报告
Zheng Quan Ri Bao· 2025-04-24 23:33
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:001376 证券简称:百通能源 公告编号:2025-016 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整,不存在虚假记载、 误导性陈述或重大遗漏,并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明:保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □是 R否 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 R否 (二) 非经常性损益项目和金额 R适用 □不适用 单位:元 其他符合非经常性损益定义的损益项目的具体情况 适用 □不适用 "其他符合非经常性损益定义的损益项目"为公司2025年1-3月收到的个税手续费返还,金额为293,547.16 元。 将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 R不适用 ...
深圳市兆驰股份有限公司2025年第一季度报告
Core Viewpoint - The company has released its first quarter report, ensuring the accuracy and completeness of the financial information disclosed, with no significant omissions or misleading statements [2][3]. Financial Data Summary - Inventory increased by 1,181.36 million yuan, a growth of 34.67%, primarily due to the need to stock core raw materials to meet order demands [5]. - Long-term prepaid expenses rose by 14.62 million yuan, a growth of 30.75%, mainly due to increased renovation costs during the reporting period [5]. - Employee compensation payable decreased by 96.27 million yuan, a decline of 42.55%, as a result of payments made for last year's employee salaries [5]. - Taxes and surcharges increased by 4.19 million yuan, a growth of 53.57%, attributed to increased property tax for the second phase of the industrial park [5]. - Investment income grew by 0.91 million yuan, a rise of 109.41%, due to increased returns from bank products [5]. - Credit impairment losses decreased by 19.05 million yuan, a decline of 173.60%, as the company recovered some receivables [5]. - Asset impairment losses increased by 29.62 million yuan, a growth of 10,857.75%, due to changes in the net realizable value of inventory [5]. - Gains from asset disposals increased by 1.37 million yuan, a rise of 840.71%, due to asset disposals during the reporting period [5]. - Non-operating income rose by 12.32 million yuan, a growth of 2,309.16%, primarily from insurance claims received [5]. - Non-operating expenses increased by 2.58 million yuan, a rise of 81.85%, due to an increase in the scrapping of non-current assets [5]. - Income tax expenses increased by 14.50 million yuan, a growth of 58.98%, due to the completion of deductible losses, leading to a rise in taxable income [5]. - Minority interest profit decreased by 16.14 million yuan, a decline of 41.13%, due to reduced profits from non-wholly-owned subsidiaries [5]. - Net cash flow from investing activities increased by 1,836.76 million yuan, a growth of 84.65%, due to significant cash outflows from large fixed-term deposits in the previous year [5]. - Net cash flow from financing activities decreased by 681.31 million yuan, a decline of 87.95%, as the previous year saw increased financing for subsidiary business expansion [5].
天山铝业集团股份有限公司2025年第一季度报告
Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, with no false records or misleading statements [2][3] - The quarterly report has not been audited [3][7] Financial Data - The company does not require retrospective adjustments or restatements of previous accounting data [3] - There are no non-recurring profit and loss items applicable for the current quarter [3] - The company has not defined any non-recurring profit and loss items as recurring [3] Shareholder Information - The total number of ordinary shareholders and the situation of the top ten shareholders are not disclosed in the provided documents [5] - There are no changes in the top ten shareholders due to securities lending activities [5] Other Important Matters - The company has changed its website to http://www.tslyjt.com and its email to 002532@tslyjt.com [5]
江苏永鼎股份有限公司2025年第一季度报告
Core Viewpoint - The company has reported on the transfer of significant equity stakes in its subsidiaries, which may impact its financial performance and investment outlook [5][6]. Financial Data - The quarterly financial report for the first quarter of 2025 has not been audited [3][7]. - The company confirmed that the financial information presented is accurate and complete, with no significant omissions [2][4]. Shareholder Information - The company disclosed that it has transferred 82.34% equity stakes in two subsidiaries, Shanghai Dongjiao Real Estate Development Co., Ltd. and Shanghai Dongjing Real Estate Development Co., Ltd., for a total price of approximately 527 million RMB [5]. - The company’s joint venture, Dongchang Investment, reported a net profit attributable to shareholders of 58.46 million RMB for the first quarter of 2025, with the company recognizing an investment income of 29.23 million RMB [6]. Other Important Information - The company has completed the necessary registration changes following the equity transfer, indicating a shift in its investment strategy [6].
海正药业2024年净利润超6亿元,但营收下滑5.65%暴露隐忧
Jin Rong Jie· 2025-03-28 14:45
Core Viewpoint - Haizheng Pharmaceutical reported a revenue decline of 5.65% in 2024, while achieving a net profit of 601 million yuan, indicating a mixed performance with concerns over market competitiveness [1][4][5]. Revenue Decline: Core Business Struggles - The company's revenue for 2024 was 9.787 billion yuan, marking a second consecutive year of decline, highlighting weak growth in core business areas despite efforts in traditional pharmaceutical sectors [4]. - In the pharmaceutical formulation sector, Haizheng ranked 26th among Chinese pharmaceutical companies according to IQVIA, but this did not translate into significant revenue growth [4]. - The e-commerce segment saw substantial growth in key products like Yisuo Jia and Mei Man, yet overall contributions to revenue remained limited [4]. - New product launches in the export formulation business had minimal impact on overall revenue due to small initial profit margins [4]. Net Profit Growth: Reliance on Non-Recurring Gains - The net profit of 601 million yuan represented a turnaround from losses, with a non-recurring profit of 423 million yuan indicating reliance on short-term measures rather than sustainable growth [5][6]. - Profit growth was attributed to improved resource allocation and management efficiency, but these effects are more short-term in nature [5]. Emerging Business: Slow Development, Untapped Potential - Haizheng's expansion into emerging sectors like health, medical aesthetics, and synthetic biology has been slow, with limited immediate revenue impact [7]. - The company has developed over ten products in areas such as orthopedic calcium supplements and liver protection, but their market performance remains to be validated [7]. - In the medical aesthetics sector, while strategic planning is in place, only two products have been initiated, and twelve are in preliminary research, indicating a need for time to assess market viability [7].